세계의 혈관육종 치료(Angiosarcoma Treatment) 시장은 2022년 2억 5,310만 달러였으며, 2023-2030년의 예측 기간 동안 CAGR 6.4%로 추이하여, 2030년에는 4억 1,230만 달러에 달할 것으로 예측됩니다.
혈관육종은 신체 어디에서나 발생할 수 있지만 피부, 유방, 간, 비장에서 가장 자주 발생합니다. 글로벌 혈관육종 치료 시장은 표적 치료법의 채택으로 인해 최근 몇 년 동안 상당한 성장을 목격했습니다. 예를 들어, 혈관육종에서 조절되는 혈관 내피 성장 인자는 파조파닙 및 레고라페닙과 같은 티로신 키나아제 억제제의 표적이 될 수 있습니다.
또한 임상 시험 증가, 협업 증가, 연구 개발과 같은 중요한 성장 동인이 향후 시장 성장을 이끌고 있습니다. 미국 및 캐나다와 같은 국가에서 기술 발전이 크게 증가함에 따라 시장은 북미 지역의 수요가 증가하고 있습니다. Amgen Inc., Eli Lilly, and Company 및 Genentech Inc.와 같은 주요 기업이 시장에서 적극적으로 활동하고 있습니다.
역학
혈관육종 치료 연구개발 증가
세계의 혈관육종 치료 시장은 최근 다양한 연구 및 개발로 인해 상당한 성장을 목격했습니다. 혈관육종은 일반적으로 병력과 임상 및 영상 소견을 바탕으로 진단됩니다. 또한 혈관육종 치료에 대한 고급 연구 및 개발은 시장 성장을 가속화하는 데 도움이됩니다.
예를 들어, 2022년 11월에 발표된 'Cutaneous angiosarcoma treated with taxane-based chemoradiotherapy(탁산계 화학 방사선 요법으로 치료되는 피부 혈관육종)'라고 표기하는 논문에 의하면, 임상 연구에 따르면 파클리탁셀 및 도세탁셀과 같은 탁산 유래 제제가 피부 혈관육종 치료를위한 1차 화학 요법으로 중요하다는 사실이 밝혀졌습니다. 또한 탁산을 사용한 화학 방사선 요법은 수술이나 방사선 요법에 비해 전체 생존율을 크게 개선하여 높은 반응률을 달성했습니다. 따라서 위의 요인은 예측 기간 동안 시장 성장을 촉진하는 데 도움이됩니다.
혈관육종 치료의 기술적 진보 증가
혈관육종은 혈관과 림프관의 내벽에서 발생하며 주요 기업의 주요 발전은 시장 성장을 주도하는 데 도움이됩니다. 피부는 가장 많이 영향을 받는 부위로 약 57.21%가 피부 혈관육종입니다. 이러한 효과적인 발전은 연구 발견을 새로운 치료법으로 전환하고 수십억 명의 혈관육종 환자를 위한 치료를 개선하는 데 도움이 됩니다.
예를 들어, 2023년 4월 스프링거 저널(Springer Journal)잡지가 발표한 논문에서는 공간 전사체학이 아시아 두경부 혈관육종의 위상학적 면역 지형을 밝혀냈다는 내용의 논문을 발표했습니다. 이 논문은 혈관육종의 위상학적 종양 면역 지형을 밝혀냄으로써 UV 시그니처와 HHV-7의 유무로 특징지어지는 대표적인 사례에 대해 10x Genomics Visium 플랫폼을 사용하여 공간 전사체 프로파일링을 수행한 것입니다. 따라서 위의 요인으로 인해 시장은 예측 기간 동안 활성화 될 것으로 예상됩니다.
림프관육종과 관련된 합병증이 시장 성장을 방해할 것으로 예상됨
림프관 육종의 합병증에는 봉와직염, 근골격계 통증, 심리적 스트레스 및 악성 종양 위험 증가가 포함됩니다. 봉와직염은 일반적으로 경구 항생제와 함께 발생하며 봉와직염은 피부 아래의 진피와 피하 조직의 박테리아 감염이며 림프관 육종과 관련된 가장 흔한 합병증입니다. 따라서 위의 요인으로 인해 시장은 예측 기간 동안 방해를 받을 것으로 예상됩니다.
Global Angiosarcoma Treatment Market reached US$ 253.1 million in 2022 and is expected to reach US$ 412.3 million by 2030 growing with a CAGR of 6.4% during the forecast period 2023-2030.
Angiosarcoma can develop anywhere in the body but most often occur in the skin, breast, liver, and spleen. The global angiosarcoma treatment market has witnessed significant growth in recent years due to the adoption of targeted therapies. For instance, vascular endothelial growth factor which is regulated in angiosarcoma can be targeted by tyrosine kinase inhibitors such as pazopanib and regorafenib.
Furthermore, significant growth drivers such as increasing clinical trials, increasing collaborations, and research and developments give rise to future market growth. Due to the massive rise in technological advancements in countries like the U.S. and Canada, the market is experiencing a rise in demand from North American regions. Significant key players like Amgen Inc., Eli Lilly, and Company, Genentech Inc., and others are actively operating in the market.
Dynamics
Increasing Research and Developments for Angiosarcoma Treatment
The global angiosarcoma treatment market has witnessed significant growth due to various recent research and developments. Angiosarcoma is usually diagnosed on the basis of medical history and clinical and imaging findings. Also, advanced research and developments in treating angiosarcoma help to accelerate market growth.
For instance, according an article entitled Cutaneous angiosarcoma treated with taxane-based chemoradiotherapy published on November 2022 states that clinical studies have suggested the importance of taxane-derived agents such as paclitaxel and docetaxel as first-line chemotherapy for treatment of cutaneous angiosarcoma. In addition, chemoradiotherapy with taxanes achieved a high response rate with significant improvement in overall survival compared with surgery or radiotherapy. Thus, the above factors help to boost the market growth in the forecast period.
Rising Technological Advancements for Angiosarcoma Treatment
Angiosarcoma develops in the inner lining of blood vessels and lymph vessels and the major advancements from major companies help to drive market growth. Skin is the most affected area with approximately 57.21% of cases being cutaneous angiosarcoma. These effective advancements help to transform research discoveries into new treatments and improve care for billions of people with angiosarcoma.
For instance, Springer Journal published an article in April 2023, states that spatial transcriptomics reveals topological immune landscapes of Asian head and neck angiosarcoma. It involves spatial transcriptomic profiling using the 10x Genomics Visium platform that is performed on representative cases characterized by the presence or absence of UV signatures and HHV-7 by revealing the topological tumor immune landscape of angiosarcoma. Thus, owing to the above factors the market is expected to boost over the forecast period.
Complications Associated with Lymphangiosarcoma is Expected to Hamper Global Market Growth
Complications of lymphangiosarcoma include cellulitis, musculoskeletal pain, psychological stress, and an increased risk of malignancy. Cellulitis usually occurs with oral antibiotics and cellulitis is a bacterial infection of the dermis and subcutaneous tissues underneath the skin and is the most common complication associated with lymphangiosarcoma. Thus, owing to the above factors the market is expected to hamper over the forecast period.
The global angiosarcoma treatment market is segmented based on type, treatment, end users, and region.
Immunotherapy from the Treatment Segment Accounted for Approximately 38.5% of the Global Angiosarcoma Treatment Market Share
The rising clinical trials of angiosarcoma globally have contributed to the growing demand for angiosarcoma treatment. Immunotherapy includes drugs that activate the immune system that modify the immune system cells to target tumor cells and monoclonal antibodies, checkpoint inhibitors, and vaccines are the common types of immunotherapies.
For instance, according to clinicalTrials.gov, on April 5, 2023, M.D. Anderson Cancer Center conducted a clinical trial on Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma. The main aim is to determine the safety, toxicity, and feasibility of delivering autologous dendritic cells (DCs) loaded with tumor lysate plus mRNA to patients with cutaneous head & neck angiosarcoma as adjuvant therapy. Thus, the above factors help to acceleratethe market growth.
Geographical Penetration
North America Accounted for Approximately 38.4% of the Market Share in 2022
North America has maintained a significant proportion of the angiosarcoma market in recent years, and this trend is anticipated to continue throughout the forecast period due to the factors such as an increase in healthcare expenditures, increasing research and developments, and technological advancements in angiosarcoma treatment.
For instance, according to the National Health Expenditure Account (NHEA), the total annual healthcare expenditure in the United States is increased by 2.7% to $4.3 trillion. Physician spending grew by an average of 3.8% per year while hospital services (4.5%) and clinical services (6.6%) had higher growth rates.
The major global players in the market include: Novartis AG,Bayer AG,Sanofi,Amgen Inc.,Eli Lilly and Company,Genentech Inc.,Janssen Pharmaceuticals, AbbVie Inc, Bausch Health, GlaxoSmithKline Plc.among others.
The COVID-19 pandemic has had a significant impact on the angiosarcoma treatment market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in angiosarcoma treatment research. Clinical trials are vital for developing new treatments and improving outcomes in the angiosarcoma treatment market.
However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies. Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the angiosarcoma treatment market is expected to be moderately affected over the forecast period.
By Type
By Treatment
By End Users
By Region
U.S.
Canada
Mexico
Germany
U.K.
France
Italy
Spain
Rest of Europe
Brazil
Argentina
Rest of South America
China
India
Japan
Australia
Rest of Asia-Pacific
The global angiosarcoma treatment market report would provide approximately 69 tables, 70 figures, and 195 Pages.
LIST NOT EXHAUSTIVE